Chimerix, Inc. (NASDAQ:CMRX) Sees Significant Growth in Short Interest

Chimerix, Inc. (NASDAQ:CMRX) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 3,440,000 shares, an increase of 431.1% from the November 30th total of 647,700 shares. Approximately 4.3% of the company’s stock are sold short. Based on an average trading volume of 3,750,000 shares, the days-to-cover ratio is currently 0.9 days.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CMRX. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Chimerix in a report on Wednesday, December 11th. Wedbush reissued an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a research report on Tuesday, December 10th.

Chimerix Stock Performance

NASDAQ CMRX traded up $0.24 on Friday, reaching $3.46. The stock had a trading volume of 2,217,404 shares, compared to its average volume of 1,270,049. The stock has a market cap of $311.18 million, a P/E ratio of -3.68 and a beta of 1.02. Chimerix has a 12-month low of $0.75 and a 12-month high of $3.61. The business’s 50-day moving average price is $1.50 and its 200 day moving average price is $1.10.

Institutional Trading of Chimerix

Several institutional investors and hedge funds have recently bought and sold shares of CMRX. Connor Clark & Lunn Investment Management Ltd. increased its stake in Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares during the period. Valeo Financial Advisors LLC increased its position in Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 69,505 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Chimerix during the 2nd quarter valued at approximately $137,000. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.